臨床泌尿器科71巻7号

2017年06月発行

特集 去勢抵抗性前立腺癌（CRPC）─Key Questionsに答える

リキッドバイオプシーの現状と展望

著者： 井川掌¹

所属機関： ¹久留米大学医学部泌尿器科学講座

ページ範囲：P.524 - P.529

文献概要

Key Question
▶ リキッドバイオプシーとは何ですか？　また，どのような有用性があるのでしょうか？

Direct Answer

・血液を主体とする液性試料を用いてそのなかに含まれる癌細胞や核酸などを種々の技術により検出し，その量や遺伝子変異などを解析する手法です．

・得られた情報は癌の包括的状態や治療効果判定，治療薬剤選択などに役立てることができます．

・従来の組織生検に比較して，より低侵襲に繰り返し試料を得ることができることが利点の1つです．

参考文献

1） Vilar E and Tabernero J : Cancer : Pinprick diagnostics. Nature 486 : 482─483, 2012

2） Diaz LA Jr, Williams RT, Wu J, et al : The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486 : 537─540, 2012

3） Ashworth TR : A case of cancer in which cells similar to those in the tumour were seen in the blood after death. Aust Med J 14 : 146─149, 1986

4） Parkinson DR, Dracopoli N, Petty BG, et al : Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med 10 : 138, 2012

5） Miller MC, Doyle GV and Terstappen LW : Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol 2010 : 617421, 2010

6） Cristofanilli M, Budd GT, Ellis MJ, et al : Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351 : 781─791, 2004

7） Stroun M, Lyautey J, Lederrey C, et al : About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 313 : 139─142, 2001

8） de Bono JS, Scher HI, Montgomery RB, et al : Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer. Clin. Cancer Res 14 : 6302─6309, 2008

9） Olmos D, Arkenau HT, Ang JE, et al : Circulating tumour cell （CTC） counts as intermediate end points in castration-resistant prostate cancer CRPC : a single-centre experience. Ann Oncol 20 : 27─33, 2008

10） Danila DC, Anand A, Sung CC, et al : TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 60 : 897─904, 2011

11） Goldkorn A, Ely B, Quinn DI, et al : Circulating tumor cell counts are prognostic of overall survival in SWOG S0421 : a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32 : 1136─1142, 2014

12） Miyamoto DT, Lee RJ, Stott SL, et al : Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2 : 995─1003, 2012

13） Antonarakis ES, Lu C, Wang H, et al : AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 : 1028─1038, 2014

14） Antonarakis ES, Lu C, Luber B, et al : Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol 1 : 582─591, 2015

15） Beltran H, Jendrisak A, Landers M, et al : The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clin Cancer Res 22 : 1510─1519, 2016

16） Gao D, Vela I, Sboner A, et al : Organoid cultures derived from patients with advanced prostate cancer. Cell 159 : 176─187, 2014

17） Azad AA, Volik SV, Wyatt AW, et al : Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA : Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin Cancer Res 21 : 2315─2324, 2015

18） Hegemann M, Stenzl A, Bedke J, et al : Liquid biopsy : ready to guide therapy in advanced prostate cancer? BJU Int 118 : 855─863, 2016

19） Yaman AF, Kovancilar M, Dizdar Y, et al : Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 32 : 583─588, 2011

20） Shen J, Hruby GW, McKiernan JM, et al : Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 72 : 1469─1477, 2012